- Conditions
- High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma, Endoscopic Surgical Procedure, Transitional Epithelial Cells
- Interventions
- MK-3475 and BCG
- Drug
- Lead sponsor
- Shaheen Alanee
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Bladder Neoplasms
- Interventions
- Mycobacterial cell wall-DNA complex
- Drug
- Lead sponsor
- Bioniche Life Sciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • San Diego, California • New Britain, Connecticut + 17 more
- Conditions
- Superficial Bladder Cancer
- Interventions
- ADSTILADRIN
- Biological
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 34
- States / cities
- Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 29 more
- Conditions
- Bladder Urothelial Carcinoma In Situ, Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Superficial Bladder Urothelial Carcinoma
- Interventions
- Acupuncture Therapy, BCG Solution, Best Practice, Quality-of-Life Assessment, Questionnaire Administration
- Device · Biological · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Bladder Cancer
- Interventions
- Mycobacterial Cell-Wall DNA Complex, Bacillus Calmette-Guerin
- Biological
- Lead sponsor
- Bioniche Life Sciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 14
- States / cities
- Laguna Hills, California • Los Angeles, California • San Diego, California + 11 more
- Conditions
- Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Interventions
- EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy)
- Drug
- Lead sponsor
- enGene, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 43 more
- Conditions
- Bladder Cancer, High Risk Superficial
- Interventions
- Bacillus Calmette-Guérin (BCG)
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more
- Conditions
- Recurrent Bladder Cancer, Transitional Cell Carcinoma of the Bladder
- Interventions
- sunitinib malate, immunohistochemistry staining method, TdT-mediated dUTP nick end labeling assay, light microscopy, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Bladder Cancer
- Interventions
- Intravenous MK-3475/ Intravesical BCG
- Drug
- Lead sponsor
- Southern Illinois University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 3
- States / cities
- Springfield, Illinois • Detroit, Michigan
- Conditions
- Basal Cell Carcinoma
- Interventions
- vismodegib (150 mg PO daily)
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- St Louis, Missouri